Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) EPS (Weighted Average and Diluted) (2021 - 2026)

Design Therapeutics' EPS (Weighted Average and Diluted) history spans 1 years, with the latest figure at -$0.2 for Q4 2021.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.2 in Q4 2021 year-over-year; TTM through Dec 2021 was -$0.78, a N/A change, with the full-year FY2025 number at -$1.22, down 38.64% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.2 in Q4 2021 for Design Therapeutics, up from -$0.21 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for DSGN hit a ceiling of -$0.14 in Q2 2021 and a floor of -$0.21 in Q3 2021.